Eyam Vaccines and Immunotherapeutics Secures Global Health Grant to Advance Gemini Expression Platform

VANCOUVER, BC / ACCESSWIRE / September 10, 2024 / Eyam Vaccines and Immunotherapeutics is pleased to announce a new grant from the Bill & Melinda Gates Foundation to support the further development of its Gemini expression platform. The goal of this project is to further develop the platform's potential to deliver durable expression of a protein therapeutic, marking an important step in demonstrating the broader applications of this innovative technology.

This study will utilize a monoclonal antibody as a tool to explore how effectively the expression platform can generate sustained expression of the therapeutic protein.

"This grant represents a key milestone for our Gemini platform," said Ryan M. Thomas, CEO of Eyam Vaccines. "By demonstrating the potential of this technology to produce durable protein therapeutics, we can unlock new opportunities for developing long-lasting, low-cost treatments across a range of diseases."

Dr. Terry Pearson, member of Eyam's Board of Directors and an expert in monoclonal antibody technologies emphasized, "The ability of the Gemini expression platform to provide sustained protein expression paves the way for improving monoclonal antibody therapies. This technology could substantially enhance treatment effectiveness and patient compliance by reducing the need for frequent dosing."

Advancing the Gemini Platform

Eyam's Gemini Platform represents a breakthrough in the delivery of therapeutic proteins, offering the possibility of sustained therapeutic effects with minimal dosing. This capability could transform how protein-based therapies are delivered, potentially reducing the need for frequent treatments and enhancing patient outcomes.

Dr. Wilfred Jefferies, Chief Scientific Officer at Eyam, remarked, "The Gemini Platform represents a significant advance in therapeutic delivery. Its novel approach to achieving consistent, long-term protein expression could redefine how we develop and administer protein-based therapies."

Next Steps

The proof-of-concept study will begin immediately, focusing on preclinical evaluations to validate the platform's ability to deliver consistent, long-term protein expression. If successful, this project could pave the way for further exploration of the Gemini expression platform across a range of therapeutic areas beyond infectious diseases.

About Eyam Vaccines and Immunotherapeutics

Eyam Vaccines and Immunotherapeutics is dedicated to revolutionizing healthcare through the development of advanced therapeutic and vaccine platforms. The company's work spans infectious diseases, oncology, chronic diseases, and animal health.

Eyam is named in honour of the historic plague village in Derbyshire, England. The residents of Eyam heroically quarantined themselves within the village boundaries to prevent the disease from spreading further, braving near certain death. Today, Eyam honors their heroic sacrifice by advancing next-generation technologies to prevent and treat disease on a global scale.

For more information, please contact:

Samad Raza
Business Analyst
sraza@eyamhealth.com
+1 (778) 381-1075

SOURCE: Eyam Vaccines and Immunotherapeutics